Applications of Methyl 4-(4-Fluorophenyl)-6-Isopropyl-2-[(N-Methyl-N-Methylsulfonyl)Amino]Pyrimidine-5-Carboxylate in Industrial Manufacturing

Methyl 4-(4-Fluorophenyl)-6-Isopropyl-2-[(N-Methyl-N-Methylsulfonyl)Amino]Pyrimidine-5-Carboxylate serves as a specialized intermediate in advanced chemical synthesis, supporting critical transformations across select sectors. As the original manufacturer, we directly supply this compound for integration in regulated pharmaceutical active ingredient synthesis, crop protection agent development, veterinary drug formulations, and specialty research chemicals. Only proven, compliant downstream applications are addressed below, with a focus on the details relevant to formulators and plant engineers.

1. Pharmaceutical API Intermediate Synthesis

This compound enables the construction of advanced pyrimidine scaffolds during the multistep synthesis of next-generation antihypertensive agents. Its functionalized structure supports late-stage transformations like selective N-alkylation and controlled ester hydrolysis in GMP-regulated pharmaceutical production. Manufacturing plants incorporate it using established process controls to minimize impurity formation, with integration validated through route-specific analytical verification. Batch records and cleaning validation ensure its traceability throughout the API production line.

Industry compliance standards

• ICH Q7 GMP guidelines for active pharmaceutical ingredient manufacturing
• US FDA 21 CFR Part 210/211
• European Pharmacopoeia (Ph. Eur.) monographs for process intermediates
• EDQM TSE/BSE risk assessment protocols

Typical usage ratio

• Base charge of 0.8–1.2 molar equivalents per targeted API batch, dependent on yield optimization metrics and process step

Downstream process integration

• Loaded during Stage-2 or Stage-3 condensation reactions following initial core pyrimidine assembly and prior to API-side chain functionalization; monitored via HPLC quantitation

Final product types

• Finished pharmaceutical active ingredients (e.g., selective angiotensin II receptor antagonists)
• Bulk APIs for formulation into tablets, capsules, and injectables

2. Agrochemical Active Ingredient Intermediate

In the crop protection sector, this material is applied as a key intermediate for the targeted synthesis of pyrimidine-based selective herbicides, especially fluorinated analogs with enhanced metabolic stability. Agrochemical synthesis facilities handle it in closed reactor systems, where formulation chemists tune its dose precisely according to downstream halogenation and isopropylation reaction requirements, ensuring compliance with international safety and purity specifications for actives destined for export.

Industry compliance standards

• FAO and WHO Specifications for Plant Protection Products
• ISO 9001:2015 quality management system for agchem manufacturing
• REACH Registration (EC No. 1907/2006) substance-related obligations
• European Regulation (EC) No 1107/2009 for plant protection agent approval

Typical usage ratio

• Typically 1.0–1.3 molar equivalents relative to primary chlorination substrate, with adjustments based on reactivity in pilot plant batch records

Downstream process integration

• Introduced during the intermediate coupling step, prior to final etherification or sulfonamide derivatization; auxiliary solvent recovery systems active during addition

Final product types

• Technical-grade selective herbicide active ingredients (e.g., pyrimidine sulfonamides and related fluorinated herbicides)
• Bulk actives subsequently formulated into EC, SC, or WG agrochemical preparations

3. Veterinary Drug Intermediate

For veterinary pharmaceuticals, production teams use this material as an intermediate in the synthesis of advanced pyrimidine-based anti-infectives and antiparasitic compounds. The specific substitution pattern allows for late-stage process customization to meet the unique requirements of veterinary-use actives, with rigorous trace impurity controls according to VICH toxicological risk standards. It enters the synthetic route after ring closure, supporting manufacturing flexibility across multiple target molecules intended for livestock and companion animal treatments.

Industry compliance standards

• VICH GL3 Good Manufacturing Practices for Veterinary Medicinal Products
• USP and European Pharmacopoeia Veterinary Monographs
• WHO GMP for Veterinary Drugs
• ISO 9001:2015 (for animal health product production)

Typical usage ratio

• Administered at 0.9–1.1 moles per mole of target compound, with specific ratio set according to the derivative selected for animal health use

Downstream process integration

• Used in the convergent assembly phase, following initial heterocycle synthesis and prior to final methylsulfonylation and purification stages; monitored under validated manufacturing process orders

Final product types

• Veterinary active ingredients for oral or injectable formulations
• Bulk drugs for integration into livestock feed additives and pet pharmaceutical products

4. Custom Synthesis for Discovery and Development

Contract research organizations, university synthesis labs, and industrial R&D facilities order this compound as a starting material for library synthesis and structure–activity relationship studies across pharmaceutical and agrochemical programs. Our large-scale production supports custom batch requests with consistent purity profiles suitable for high-throughput screening. Research teams rely on the compound’s unique combination of pyrimidine and fluorophenyl moieties to drive lead discovery and analytical method development, complying with institutional quality compliance for experimental reproducibility.

Industry compliance standards

• GLP (Good Laboratory Practice) under OECD Principles
• Institutional Quality Assurance Systems (ISO 17025 accreditation for analytical labs)
• Internal SOPs for chemical research material handling
• Material Safety requirements per GHS and regional chemical safety guidelines

Typical usage ratio

• 1.0–1.5 equivalents per target analog during iterative combinatorial synthesis; ratio varies by research design and anticipated analog library size

Downstream process integration

• Engaged during parallel solution-phase or solid-phase synthesis workflows for lead compound generation; integrated with automated purification and analytical testing pipelines

Final product types

• Discovery-phase pharmaceutical and agrochemical lead compounds
• Analytical reference standards and validation samples for method development
• Small-molecule tool compounds for biological screening